
X
Novo Nordisk: survival of the fittest applies in diabetes and obesity market
https://pharmaphorum.com/views-and-analysis/novo-nordisk-survival-fittest-applies-diabetes-obesity-market/
Lower severe hypo risk compared with Lantus – but no cardiac benefit.
Results give advantage to Boehringer/Lilly’s Jardiance.
Oral formulation of GLP-1 drug could help cut heart attacks, tackle liver and kidney problems
Mary Szela has quit to avoid a conflict of interest.
Body cites uncertainty over manufacturer’s data.
MSD keeps pressure on BMS with EU classical Hodgkin lymphoma indication.